13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001224962
Total reported value
$6.7B
$6.7B
94 檔
27.0%
In Q1 2026, Perceptive Advisors LLC's U.S. equity holdings reached a combined market value of $6.7B, distributed across 94 disclosed stock positions.
In Q1 2026, Perceptive Advisors LLC adopted a defensive or profit-taking posture, trimming 33 positions and completely liquidating 42 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PRAX | Praxis Precision Medicines I | Stock-Other | 12.82% | -2.59% | +2.00% | |
| 2 | CELC | Celcuity Inc | Stock-Other | 6.97% | -1.95% | -1.04% | |
| 3 | ASND | Ascendis Pharma A/S | Stock-Other | 6.84% | -6.84% | EXIT | |
| 4 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 4.48% | -0.18% | +3.76% | |
| 5 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 4.08% | -4.08% | EXIT | |
| 6 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 4.03% | +0.28% | -6.78% | |
| 7 | SYRE | Spyre Therapeutics Inc | Stock-Other | 3.73% | +2.03% | +23.26% | |
| 8 | NUVL | Nuvalent Inc-a | Stock-Other | 3.16% | -0.23% | -5.08% | |
| 9 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.72% | -0.05% | -0.76% | |
| 10 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.54% | -0.73% | -8.85% | |
| 11 | APGE | Apogee Therapeutics Inc | Stock-Other | 2.53% | +0.08% | -33.91% | |
| 12 | TVTX | Travere Therapeutics Inc | Stock-Other | 2.40% | +0.80% | -3.17% | |
| 13 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 2.25% | — | — | |
| 14 | ✓ | Immatics NV | Stock-Other | 2.00% | -0.42% | — | |
| 15 | RLAY | Relay Therapeutics Inc | Stock-Other | 1.90% | +2.06% | +412.34% | |
| 16 | INBX | Inhibrx Biosciences Inc | Stock-Other | 1.90% | -0.05% | -0.69% | |
| 17 | MGTX | MeiraGTx Holdings plc | Stock-Other | 1.75% | +0.44% | — | |
| 18 | ZYME | Zymeworks Inc | Stock-Other | 1.72% | -0.08% | +7.61% | |
| 19 | SLDB | Solid Biosciences Inc | Stock-Other | 1.68% | +0.11% | +0.62% | |
| 20 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.65% | -0.75% | +34.20% | |
| 21 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.38% | +0.17% | +135.07% | |
| 22 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.34% | +0.58% | -5.49% | |
| 23 | AORT | Artivion Inc | Stock-Other | 1.17% | -0.58% | -4.94% | |
| 24 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.12% | +0.45% | +4.36% | |
| 25 | MRNA | Moderna Inc | Stock-Healthcare | 0.99% | +0.06% | — | |
| 26 | NAUT | Nautilus Biotechnology Inc | Stock-Other | 0.95% | -0.62% | — | |
| 27 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.93% | -0.34% | +4.32% | |
| 28 | ANRO | Alto Neuroscience Inc | Stock-Other | 0.88% | -0.24% | +12.64% | |
| 29 | ✓ | Engene Holdings Inc | Stock-Other | 0.78% | -0.78% | EXIT | |
| 30 | IMVT | Immunovant Inc | Stock-Other | 0.78% | +0.01% | -19.93% | |
| 31 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 0.77% | -0.46% | -2.84% | |
| 32 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.74% | -0.07% | — | |
| 33 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.74% | -0.74% | EXIT | |
| 34 | ABVX | Abivax Sa-adr | Stock-Other | 0.72% | -0.57% | -28.25% | |
| 35 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 0.66% | -0.06% | +231.07% | |
| 36 | RGEN | Repligen CORP | Stock-Healthcare | 0.65% | -0.14% | -11.09% | |
| 37 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 0.63% | -0.02% | — | |
| 38 | DMRA | Damora Therapeutics Inc | Stock-Other | 0.62% | -0.14% | — | |
| 39 | XFOR | X4 Pharmaceuticals Inc | Stock-Other | 0.54% | +0.02% | +6.70% | |
| 40 | GH | Guardant Health Inc | Stock-Healthcare | 0.54% | -0.45% | +87.50% | |
| 41 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 0.54% | -0.54% | EXIT | |
| 42 | IVVD | Invivyd Inc | Stock-Other | 0.53% | -0.29% | -4.25% | |
| 43 | SION | Sionna Therapeutics Inc | Stock-Other | 0.52% | +0.08% | -44.16% | |
| 44 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.50% | -0.06% | +0.71% | |
| 45 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.49% | +0.99% | — | |
| 46 | SABS | Sab Biotherapeutics Inc | Stock-Other | 0.48% | -0.09% | +700.75% | |
| 47 | BLTE | Belite Bio Inc - Adr | Stock-Other | 0.47% | -0.47% | EXIT | |
| 48 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.45% | -0.08% | +229.68% | |
| 49 | AXGN | Axogen Inc | Stock-Other | 0.45% | -0.28% | -11.07% | |
| 50 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.45% | -0.29% | -61.52% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | 260 | Centessa Pharmaceuticals-adr | +2.8% | +80.25% | Add |
| 2 | ASND | Ascendis Pharma A/S | +2.7% | +41.61% | Add |
| 3 | PRAX | Praxis Precision Medicines I | +2.3% | +2.00% | Add |
| 4 | SYRE | Spyre Therapeutics Inc | +1.9% | +23.26% | Add |
| 5 | RLAY | Relay Therapeutics Inc | +1.6% | +412.34% | Add |
| 6 | ROIV | Roivant Sciences Ltd. | +1.4% | +3.76% | Add |
| 7 | CELC | Celcuity Inc | +1.4% | -1.04% | Trim |
| 8 | BCRX | Biocryst Pharmaceuticals Inc | +0.9% | +135.07% | Add |
| 9 | EWTX | Edgewise Therapeutics Inc | +0.8% | -0.76% | Trim |
| 10 | CRVS | Corvus Pharmaceuticals Inc | +0.6% | +231.07% | Add |
| 11 | ORKA | Oruka Therapeutics Inc | +0.5% | -5.49% | Trim |
| 12 | NAUT | Nautilus Biotechnology Inc | +0.5% | — | Unchanged |
| 13 | SLDB | Solid Biosciences Inc | +0.5% | +0.62% | Add |
| 14 | AMLX | Amylyx Pharmaceuticals Inc | +0.5% | — | Unchanged |
| 15 | DYN | Dyne Therapeutics Inc | +0.4% | +34.20% | Add |
| 16 | PTGX | Protagonist Therapeutics Inc | +0.4% | -8.85% | Trim |
| 17 | SABS | Sab Biotherapeutics Inc | +0.4% | +700.75% | Add |
| 18 | TENX | Tenax Therapeutics Inc | +0.4% | +229.68% | Add |
| 19 | ANRO | Alto Neuroscience Inc | +0.3% | +12.64% | Add |
| 20 | MGTX | MeiraGTx Holdings plc | +0.3% | — | Unchanged |
| 21 | TNGX | Tango Therapeutics Inc | +0.3% | +57.52% | Add |
| 22 | GH | Guardant Health Inc | +0.3% | +87.50% | Add |
| 23 | AVR | Anteris Technologies Global | +0.2% | +104.45% | Add |
| 24 | CTMX | Cytomx Therapeutics Inc | +0.2% | +4.32% | Add |
| 25 | ZYME | Zymeworks Inc | +0.2% | +7.61% | Add |
| 26 | NUVL | Nuvalent Inc-a | +0.2% | -5.08% | Trim |
| 27 | LONA | Leonabio Inc | +0.1% | — | Unchanged |
| 28 | JAZZ | Jazz Pharmaceuticals plc | +0.1% | — | Unchanged |
| 29 | XFOR | X4 Pharmaceuticals Inc | +0.1% | +6.70% | Add |
| 30 | OCS | Oculis Holding AG | +0.1% | — | Unchanged |
| 31 | ✓ | Immatics NV | +0.1% | — | Unchanged |
| 32 | CELC 2.75 08-01-31Bond | Celcuity Inc | +0.1% | — | Unchanged |
| 33 | RAPP | Rapport Therapeutics Inc | +0.1% | — | Unchanged |
| 34 | ADGM | Adagio Medical Holdings Inc | 0% | — | Unchanged |
| 35 | OBIO | Orchestra Biomed Holdings In | 0% | -1.74% | Trim |
| 36 | BLLN | Billiontoone Inc Cl A | 0% | +26.09% | Add |
| 37 | AXSM | Axsome Therapeutics Inc | 0% | +0.71% | Add |
| 38 | CTNM | Contineum Therapeutics Inc-a | 0% | -14.27% | Trim |
| 39 | COGT | Cogent Biosciences Inc | 0% | — | Unchanged |
| 40 | RVMDW | Revolution Medicines Inc-28 | 0% | — | Unchanged |
| 41 | IRD | Opus Genetics Inc | — | -57.55% | Trim |
| 42 | ✓ | Connect Biopharma Hldgs LTD | — | — | Unchanged |
| 43 | OM | Outset Medical Inc | — | — | Unchanged |
| 44 | MDLN | Medline Inc-cl A | — | — | Unchanged |
| 45 | ENSC | Ensysce Biosciences Inc | — | — | Unchanged |
| 46 | PTN | Palatin Technologies Inc | — | -11.51% | Trim |
| 47 | SRZNW | Surrozen Inc-cw25 | — | — | Unchanged |
| 48 | AXGN | Axogen Inc | 0% | -11.07% | Trim |
| 49 | CPIX | Cumberland Pharmaceuticals | 0% | -42.25% | Trim |
| 50 | AVTX | Avalo Therapeutics Inc | 0% | — | Unchanged |
According to official SEC Form 13F filings, Perceptive Advisors LLC reported a total U.S. public equity portfolio value of $6.7B across 94 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PRAX, CELC, ASND) accounted for 27.0% of total reported equity market value during Q1 2026.
Top New Position Initiated
MRNA
市值: $50.8M
Top Position Liquidated / Trimmed
XBI
前期市值: $134.1M
During Q1 2026, Perceptive Advisors LLC's top holdings by market value included PRAX (12.8%)、CELC (7.0%)、ASND (6.8%). The largest single position, PRAX, represented 12.8% of total portfolio value.
In Q1 2026, Perceptive Advisors LLC made 118 total portfolio adjustments, initiating 20 new buys, adding to 23 positions, trimming 33 holdings, and fully liquidating 42 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.